Tampa, FLNCT06760156Now EnrollingIRB Ready

Large B-cell Lymphoma Clinical Trial in Tampa, FL

Access cutting-edge large b-cell lymphoma treatment through this phase 2 clinical trial at a research site in Tampa. Study-provided care at no cost to qualified participants.

Sponsored by H. Lee Moffitt Cancer Center and Research Institute

Quick Self-Assessment

See if you qualify for this Tampa location

Preparing your pre-screening questions…

Expert Care in Tampa

Access large b-cell lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related large b-cell lymphoma treatment provided free

Apply for This Tampa Location

Check if you qualify for this large b-cell lymphoma clinical trial in Tampa, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Tampa

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Tampa site if eligible
  4. 4Begin participation

About This Large B-cell Lymphoma Study in Tampa

The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Who Can Participate

Inclusion Criteria

Patients must have histologically documented history of large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
Adult males or females must be of age ≥18 years or older at time of signing informed consent.
Patients must be capable of understanding the protocol with willingness to comply with all study procedures including availability for the duration of the study.
Patients must be able to understand and willing to sign a written informed consent form (ICF) document.
Measurable PET/CT positive disease (partial response or stable disease per the 2014 Lugano Classification) on PET/CT obtained at least 21 days after, but no more than 60 days after CAR-T with axicabtagene-ciloleucel.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Participants must have adequate organ and bone marrow function.
Patients must have adequate hepatic function.
Patients must have adequate renal function.
Baseline Oxygen Saturation \>92% on room air.
Females of reproductive potential must avoid pregnancy for at least 4 weeks before beginning lenalidomide therapy, during therapy, during dose interruptions and for at least 4 weeks after completing therapy. Females must commit either to abstain continuously from heterosexual sexual intercourse or to use two methods of reliable birth control, beginning 4 weeks prior to initiating treatment with lenalidomide, during therapy, during dose interruptions and continuing for 4 weeks following discontinuation of lenalidomide therapy.

Exclusion Criteria

Patients who are currently receiving or who have received any investigational study agent ≤4 weeks prior to the screening visit are ineligible.
Detectable cerebrospinal fluid malignant cells, brain metastases, or active central nervous system (CNS) lymphoma after CAR T cell administration.
History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.
Presence of bacterial, viral, fungal, and/or other infection of any origin that is uncontrolled and/or requires intravenous (IV) antimicrobials for treatment.
Known cardiac atrial or cardiac ventricular lymphoma involvement.
History of symptomatic pulmonary embolism within 6 months of enrollment.
Known primary immunodeficiency.
History of autoimmune disease (e.g. Crohn's disease, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years.
History of hypersensitivity, allergy or severe skin reactions to lenalidomide (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis).
History of hypersensitivity, allergy or previous exposure to tafasitamab.
Any medical condition deemed by the treating physician likely to interfere with assessment of safety or efficacy of study treatment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tampa?

Yes, this clinical trial (NCT06760156) has an active research site in Tampa, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Large B-cell Lymphoma Treatment Options in Tampa, FL

If you're searching for large b-cell lymphoma treatment options in Tampa, FL, this clinical trial (NCT06760156) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tampa research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced large b-cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all large b-cell lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Tampa, FL

See all lymphoma clinical trials recruiting in Tampa — not just this study.

Browse Lymphoma Trials in Tampa →

Browse More Trials by Condition

Lymphoma TrialsDiffuse Large B-Cell Lymphoma TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Tampa?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Tampa, FL